NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Malignant glioma
Date of first enrollment	01/8/2009
Target sample size	31
Countries of recruitment
Study type	INTERVENTIONAL
Intervention(s)	Intervention name : R435(Bevacizumab) Dosage And administration of the intervention : 10mg/kg, every 2 weeks Control intervention name : - Dosage And administration of the control intervention : -

Outcome(s)

Primary Outcome	6-month progression free survival
Secondary Outcome	1-year survival rate, Progression free survival, Overall response rate, Overall survival, Disease control rate

Key inclusion & exclusion criteria

Age minimum	20
Age maximum
Gender	BOTH
Include criteria	-Age >= 20 years -Histologically confirmed malignant glioma -All patients must have received prior temozolomide and prior radiation therapy for malignant glioma. -No evidence of recent hemorrhage on baseline MRI of the brain. -Karnofsky Performance Status >= 70%
Exclude criteria	-The patient has received more than two regimens for malignant glioma. -History of hemoptysis(>=Grade2) within 1 month before randomization. -Serious non-healing wound or untreated bone fracture.